GEBNX
Price
$9.99
Change
+$0.05 (+0.50%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

GEBNX vs RNWFX

Header iconGEBNX vs RNWFX Comparison
Open Charts GEBNX vs RNWFXBanner chart's image
Goldman Sachs ESG Em Mkts Eq I
Price$9.99
Change+$0.05 (+0.50%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
GEBNX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GEBNX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GEBNX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. GEBNX (21.8M). RNWFX (1.51) and GEBNX (1.50) have matching dividends . GEBNX was incepted earlier than RNWFX: GEBNX (7 years) vs RNWFX (23 years). GEBNX is a more actively managed with annual turnover of: 54.00 vs. RNWFX (32.00). GEBNX has a lower initial minimum investment than RNWFX: GEBNX (0) vs RNWFX (250). GEBNX annual gain was more profitable for investors over the last year : 13.05 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. GEBNX (-2.29).
GEBNXRNWFXGEBNX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence7 years23 years-
Gain YTD11.0524.549243%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets21.8M62.2B0%
Annual Yield % from dividends1.501.51100%
Returns for 1 year13.055.86223%
Returns for 3 years-17.34-5.10340%
Returns for 5 years-2.2914.39-16%
Returns for 10 yearsN/A42.67-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics